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Herpes simplex virus 1 (HSV-1) is a common virus that can rarely invade the human central
nervous system (CNS), causing devastating encephalitis. The permissiveness to HSV-
1 of the various relevant cell types of the CNS, neurons, astrocytes, oligodendrocytes,
and microglia cells, as well as their response to viral infection, has been extensively
studied in humans and other animals. Nevertheless, human CNS cell-based models of
anti-HSV-1 immunity are of particular importance, as responses to any given neurotropic
virus may differ between humans and other animals. Human CNS neuron cell lines as
well as primary human CNS neurons, astrocytes, and microglia cells cultured/isolated
from embryos or cadavers, have enabled the study of cell-autonomous anti-HSV-1
immunity in vitro. However, the paucity of biological samples and their lack of purity
have hindered progress in the field, which furthermore suffers from the absence of
testable primary human oligodendrocytes. Recently, the authors have established a
human induced pluripotent stem cells (hiPSCs)-based model of anti-HSV-1 immunity in
neurons, oligodendrocyte precursor cells, astrocytes, and neural stem cells, which has
widened the scope of possible in vitro studies while permitting in-depth explorations. This
mini-review summarizes the available data on human primary and iPSC-derived CNS cells
for anti-HSV-1 immunity. The hiPSC-mediated study of anti-viral immunity in both healthy
individuals and patients with viral encephalitis will be a powerful tool in dissecting the
disease pathogenesis of CNS infections with HSV-1 and other neurotropic viruses.
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Introduction
Herpes simplex virus 1 (HSV-1) is a double-stranded DNA virus of the α-herpesvirinae subfamily
(1). These viruses are characterized by a short replication cycle and their ability to establish latency
in sensory neurons (2). The proportion of individuals infected with HSV-1 worldwide increases
with age and can reach up to 90% in the elderly (3, 4). Primary infections by this virus lead
to a life-long latency (5) although reactivation of the virus can occur in infected individuals,
because of stress or exposure to ultraviolet radiation, leading to anterograde spread of HSV-1 to
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epithelial cells and formation of herpes labialis. Encephalitis is
a rare manifestation of HSV-1 infection and has been reported
in an estimated 1 per 250,000 cases per year (1). Approximately
one-third of cases are caused by primary infection in children (6).
Herpes simplex encephalitis (HSE) is the most common sporadic
viral encephalitis in the western countries, accounting for 20% of
the 20,000 annual cases in the Unites States (7–9). Most patients
show positive PCR results for HSV-1 DNA in their cerebral spinal
fluid. Although >70%of patients survive the diseasewith acyclovir
treatment, an inhibitor of viral DNA synthesis (10), themajority of
them consequently suffer from epilepsy, mental retardation, and
other neurological deficits (11).
Herpes simplex virus 1 reaches the central nervous system
(CNS) via cranial nerves such as olfactory and trigeminal neurons
(1). During the course of HSE, no viremia is detected in affected
patients. Within the brain, destruction of glial and neuronal cells
is detectable during the first month of disease (12), suggesting
a cytotoxic effect of HSV-1 on both neurons and astroglial cell
types. The fact that most HSE patients have intact T- and B-
cell responses to HSV-1 and are otherwise healthy (13) suggests
that intrinsic immunity to HSV-1 by CNS cell types may be a
key in controlling viral spread within the CNS. Viral suscepti-
bility and production of protective cytokines, mainly interferons
(IFNs), in the CNS of infected hosts during the course of HSV-
1 infection have been studied in vivo using mouse models, and
reviewed elsewhere (13–15). Interestingly, induction of IFNs and
other cytokines because of viral infection differs between human
and mice (16). Hence, human CNS cell-based models of anti-
HSV-1 immunity have become increasingly relevant. The disease
pathogenesis of HSE has long remained unclear, until the recent
findings that inborn error of toll-like receptor 3 (TLR3) immunity
may underlie the development of HSE in children with mutations
in TLR3, UNC93B1, TRIF, TRAF3, and TBK1 (14). The authors
herein review the studies of human CNS anti-HSV-1 immunity
based on in vitro models of human cell lines and primary cells,
as well as their recent study using human induced pluripotent
stem cells (hiPSCs)-derived neuronal cells from patients with
HSE-causing TLR3 pathway deficiencies.
Anti-HSV-1 Immunity in Neuron Cell Lines
and Primary Neurons
The human embryonic carcinoma cell line NT2 has been used as
an in vitro model in studies of CNS neurons anti-HSV-1 immu-
nity. Characterized as an equivalent of CNS neuronal progenitors,
NT2 cells are capable of differentiating into neuron-like cells in
response to retinoic acid (RA) treatment (17, 18). Differentiation
of these progenitor cells is very efficient, giving rise to 99% pure
populations of “NT2-N” neurons, which morphologically resem-
ble human primary neurons (19). These cells can be infected by
HSV-1 which induces mRNA for IFN-α and IFN-λ1 (20). NT2-
N cells also express TLR3 mRNA, which is a receptor capable
of recognizing double-stranded RNA (dsRNA) generated during
HSV-1 infections (21–23). The synthetic dsRNA polyinosinic-
polycytidylic acid [poly(I:C)], used as an agonist for TLR3 (24),
induces IFN-α and IFN-β (type I IFNs) as well as IFN-λ1 (type III
IFN) expression in NT2-N neurons in a dose-dependent manner
(19–21). Similar poly(I:C) responses were observed in BE(2)-C/m
cells differentiated on RA treatment to mature neurons (25). Pre-
treatment with poly(I:C) reduces HSV-1 replication by 80% in
NT2-N neurons, down to similar levels as observed in IFN-α,
IFN-β, IFN-λ1, and -λ2 pre-treated cells. Interestingly, HSV-1
infection in NT2-N cells induces IFN-α but not -β expression,
although the neurons can respond to this cytokine (21). Overall,
these data suggested that human CNS neuronal-like cells harbor a
functional TLR3/IFN system involved in anti-HSV-1 immunity.
To investigate the role of the TLR/IFNs pathway against HSV-
1 in a physiologically more relevant model, human primary CNS
neurons have been cultured/isolated from aborted fetuses’ cor-
tical tissues (19, 20, 26). Neuronal cultures ultimately consist
of 80–90% neurons and 10–20% astroglial cell types. TLR2 and
TLR3 are expressed throughout the CNS (27), including in human
primary neurons (28). Like in NT2-N cells, poly(I:C) can induce
elevated levels of IFN-α, IFN-β, and IFN-λ1 in primary neurons.
Pre-treatment with IFN-λ1 or -λ2 reduces HSV-1 replication
in these cells and induces IRF7 expression, a key transcription
factor creating a positive feedback loop for IFN production (29).
Globally, these results indicated that the TLR3/IFN pathway is
also critical for control of HSV-1 virus infection in primary
CNS neurons. It would also be important to look at anti-HSV-1
immunity in human peripheral nervous system (PNS) neurons,
as HSV-1 spreads along nerves of the PNS on its way to the
CNS leading to HSE, as shown by the presence of late viral
proteins in PNS neurons (30). There is, however, no reported
cell line capable of generating PNS neurons such as trigeminal
neurons. Hence, dorsal root ganglia explants from human fetal
tissues have been utilized as in vitro models (31–33). Although
HSV-1 can infect PNS neurons, their response to infection was
not studied. In addition, trigeminal ganglia (TG) removed from
cadavers and latently infected by HSV-1 showed elevated tran-
scription of IFN-γ (34). Further studies will need to address the
response of purified humanTGneurons to primary infectionwith
HSV-1.
Anti-HSV-1 Immunity in Primary Glial Cells
Central nervous system glial cells include astrocytes, oligoden-
drocytes, and microglial cells. Within the CNS, astrocytes are the
most abundant cell type (35). Culture of fetal tissues in medium
containing fetal bovine serum generates >90% pure primary
human astrocytes population upon passaging (36, 37). These cells
express primarily TLR2 and TLR3, the latter mainly on their
plasma membrane (27). In vitro poly(I:C) stimulation induces
human astrocytes to express IFN-λ1, -λ2/3 (38), and IFN-β, but
not TNF-α (36, 39), a cytokine controlling HSV-1 reactivation
rate in mice (40). Numerous other IFN stimulated genes can
be upregulated through poly(I:C) stimulation of primary human
astrocytes, including IL-6, IRF7, IFIT2, and MX1. These cells are
also permissible to HSV-1 infection (41). Recombinant IFN-λ1
and -λ2 can block HSV-1 replication in human astrocytes and
induce the expression of endogenous IFN-α through which they
exert their anti-viral activity (26). These data suggest that IFN-
λ and IFN- α have a role in anti-HSV-1 immunity at least in
astrocytes.
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Although human primary oligodendrocytes are known to pri-
marily express TLR2 and TLR3 similar to astrocytes (27), no
human primary oligodendrocyte culture system exists to date
for the study of antiviral immunity. Microglia cells clear the
CNS of dead neurons via phagocytosis (42). In contrast to neu-
rons and astrocytes, primary human microglia cells express a
wide range of TLRs, but presence of TLR3 proteins was only
observed in intracellular vesicles as assessed by immunostain-
ing (27). Furthermore, these cells are not permissive to HSV-1
replication, although immediate early viral proteins are present
in infected cells (41). Microglia cells also undergo apopto-
sis quickly following infection. Interestingly, although primary
human microglial cells stimulated by HSV-1 do not upregulate
IFN-α and -β expression levels (41), they do display elevated
levels of NF-κB activation and TNF-α production (43). TNF-
α pre-treatment blocks HSV-1 replication in primary human
astrocytes but not in primary human neurons suggesting a
cell-type specific impact of this microglia-secreted anti-viral
cytokine. The potential role of TNF-α in anti-HSV-1 immu-
nity is highlighted by the fact that treatment with inhibitors
of TNF-α was associated with HSE susceptibility in several
individuals (44).
Anti-HSV-1 Immunity in hiPSC-Derived
Neuronal Cells
In order to study the HSE pathogenesis in patients with known
disease-causing genetic etiologies, we have recently established an
hiPSC-based in vitro model of HSV-1 infection in CNS-resident
cells (45). Advances in the field of stem cell biology has allowed
for the reprogramming of human somatic cells to a pluripotent
state (46). Human pluripotent stem cells have two key proper-
ties: they can differentiate into any cells of the three germ lay-
ers (ectoderm, endoderm, mesoderm) and self-renew, potentially
replicating indefinitely in culture. Hence, we have reprogrammed
dermal fibroblasts from HSE patients to iPSCs and tested anti-
HSV-1 immunity in CNS-resident cells derived from these iPSCs.
After differentiating healthy control and patient-specific iPSCs
toward highly enriched populations of forebrain CNS neurons,
astrocytes, oligodendrocyte progenitor cells (OPCs), and neural
stem cells (NSCs), we have assessed viral susceptibility and IFNs
production in each cell type. Poly(I:C) treatment induced elevated
levels of IFN-λ1 mRNA in OPCs, and IFN-β as well as -λ1 in
neurons and astrocytes from healthy donors. Pre-treatment of
poly(I:C) as well as of recombinant IFN-α and -β inhibitedHSV-1
replication in these cell types.
We then focused on cells from two genetically defined HSE
patients, harboring an autosomal recessive complete TLR3 (47)
or UNC-93B (48) deficiency. UNC-93B is a key factor within the
TLR3/IFN pathway required to activate downstream molecular
signals (49). Susceptibility to HSV-1 was shown to be cell type and
genotype dependent. Indeed, healthy neurons and OPCs could
control viral replication, whereas UNC-93B- or TLR3-deficient
cells could not. This cellular phenotypewas related to the impaired
production of IFN-β or -λ1 in response to HSV-1 or poly(I:C) in
the same cells. On the other hand, no differences were observed
between control and patients’ NSCs and astrocytes. Hence, these
in vitro experiments demonstrated that CNS neurons and OPCs
control HSV-1 infection intrinsically in a TLR3-dependent man-
ner, although the in vivo protective role of astrocytes and NSCs
cannot be excluded. Overall, these iPSC-based experiments are in
agreement with studies based on cell lines and primary sources,
suggesting that TLR3 and IFN responses play important roles in
defense against HSV-1 infection in CNS cells (Table 1). HSE is,
to our knowledge, the first example of hiPSC-mediated modeling
of an inborn error of immunity, demonstrating a disease-relevant
immunological cellular phenotype in disease-relevant CNS cell
types.
TABLE 1 | Selected cytokines properties in human CNS cell types.
Cytokine Stimulation Cell line-derived Primary cells Control hiPSC-derived
NT2 neurons Neurons Astrocytes Microglia Neurons Astrocytes OPCs
Poly(l:C) " "   n/a n/a n/a
IFN-α HSV-1 " " n/a n/a n/a n/a n/a
Viral protection X X X n/a X X X
Poly(l:C) " " "  " " n/a
IFN-β HSV-1  " n/a n/a " " n/a
Viral protection X X X n/a X X X
Poly(l:C) " " " n/a n/a " "
IFN-λ1 HSV-1 n/a n/a n/a n/a n/a " "
Viral protection X X X n/a   
Poly(l:C) n/a n/a " n/a n/a n/a n/a
IFN-λ2/3 HSV-1 n/a n/a n/a n/a n/a n/a n/a
Viral protection X X X n/a n/a n/a n/a
Poly(l:C) n/a n/a  n/a n/a n/a n/a
TNF-α HSV-1 n/a n/a n/a " n/a n/a n/a
Viral protection   X n/a n/a n/a n/a
" stimulation upregulates the cytokine.
 stimulation does not upregulate the cytokine or showed no protective effect against HSV-1 infection.
Other cytokines can be expressed in these cell types but the authors chose to summarize here those tested.
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Conclusion
Humanneuronal cell lines as well as primary cells have allowed for
the study of anti-HSV-1 immunity of the humanCNS.Human cell
line-derived and primary CNS neurons express TLR3, display ele-
vated levels of IFN-α, -β, and -λ1 on poly(I:C) treatment, and are
permissible to HSV-1 infection. Interestingly, although poly(I:C),
IFN-α and -β can block viral replication in primary, cell line-
derived and control iPSC-derived human neurons, IFN-λ1 and -
λ2 could only do so on primary and cell line-derived neurons. Like
oligodendrocytes, human primary astrocytes express TLR3 and
were found to express high levels of IFN-λ1, -λ2/3, as well as IFN-
β on poly(I:C) stimulation. Primary astrocytes are permissible to
HSV-1 infection and are protected from viral replication by IFN-
λ1 and -λ2, whichwas not the case for control iPSC-derived astro-
cytes. Interestingly, we were able to compare directly the suscep-
tibility to HSV-1 of control hiPSC-derived CNS neurons, OPCs,
and astrocytes and demonstrated that neurons and OPCs have
an intrinsic resistance to viral replication. This control of HSV-1
replication was lost in neurons and OPCs derived from patient-
specific iPSCs with inborn errors of TLR3 pathway immunity.
Overall, these data suggest a key role for the TLR3–IFN pathway
in cell-autonomous HSV-1 immunity in neurons and OPCs, and
a potential role for this pathway in astrocytes, although this may
not be the case inmicroglia cells. Indeed, these cells do not express
TLR3 on their surface, are not permissible to HSV-1 replication,
and do not upregulate IFN-α and -β onHSV-1 infection, although
they do express the cytokine TNF-α, which can block HSV-1
replication in human astrocytes but not in neurons.
Obviously useful, experiments in primary human cells are
however limited because of the difficulty to access cell sources,
embryos, and cadavers. Furthermore, some cells are either
difficult to purify, such as TG neurons, or simply not possible to
isolate, such as oligodendrocytes. The use of hiPSCs can alleviate
these issues by providing an unlimited source of neuronal cell
types for diseasemodeling (50).Within the last 6 years, at least 190
studies have described iPSC-based human disease models (51).
Disease modeling using hiPSCs has benefited from key technical
developments including the establishment of differentiation
protocols mimicking early embryonic development steps to
generate CNS (52, 53) and PNS (54, 55) cells. Furthermore, the
advent of non-integrating methods of reprogramming (56) and
new technological breakthroughs in the field of gene editing
(57, 58) allows for the precise relationship assessment between
germline mutations and disease phenotypes. However, some tools
are still missing to completely survey the response of all neuronal
cells types infected by HSV-1 during the course of HSE. Indeed, to
date, no protocol exists for the generation of microglia cells from
hiPSCs. Hence, while a work in progress, in vitro hiPSC-based
model ofHSV-1 infection inCNS cells holds tremendous potential
for our understanding of the molecular and cellular basis of cell-
autonomous, non-hematopoietic, anti-HSV-1, intrinsic immunity
in the CNS.
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